Advancing towards the operational cure of multiple myeloma Researchers from the Spanish Myeloma Group (GEM-PETHEMA) achieve the best progression-free survival ever reported in new diagnoses September 5, 2022. 1:07 pm New research indicates that GEM/PETHEMA is advancing towards the operational cure of multiple myeloma. Specifically, its researchers have achieved the best progression-free survival ever reported in patients with newly diagnosed Multiple Myeloma. Thus, the best progression-free survival (PFS) in patients with newly diagnosed Multiple Myeloma has been surpassed by the combined result of the sequential Phase III clinical trials GEM12menos65 & GEM14main, in which the median PFS reaches 80.8 months. In this way it has been announced at the recent Congress of the International Myeloma Society in Los Angeles (USA). This trial was approved by the AEMPS in 2012. It did not start until 2013, focusing on newly diagnosed patients who could undergo a transplant. Thus, a total of 458 patients under 65 years of age were included. The clinical trial was designed to compare the clinical efficacy of two myeloablative treatment regimens. Always prior to hemopoietic stem cell transplantation. Operational cure for multiple myeloma In the words of Juan José Lahuerta, one of the coordinators of the Spanish Myeloma Group (GEM) at PETHEMA, “we could be facing an operational cure for multiple myeloma”. This term is used in the case of patients with long periods free of the disease. Specifically, in those in which the uncertainty of the possibility of relapse remains. In addition to the PFS already mentioned, Lahuerta explains that no global differences have been detected in either the toxicity profiles or the duration of the PFS between patients conditioned with BUMEL or MEL200 MEL200. Only in three groups of patients with high risk factors, in which BUMEL obtained a significant improvement in PFS compared to those treated with MEL200. All this is proof that Spanish research in Hematology is at the forefront of the world. To this, we must add the Bart Barlogie Award for best clinical researcher received by Dr. María Victoria Mateos. She is the current president of the Spanish Society of Hematology and Hemotherapy and co-coordinator of the GEM. This website uses its own and third-party cookies to compile statistical information and to be able to show you advertising related to your preferences through the analysis of your browsing. See details > AcceptPrivacy & Cookies Policy PROBOLA agen daftar situs judi slot online terpercaya dengan games pragmatic play yang sangat populer